Cidara Therapeutics is accelerating its influenza portfolio with promising clinical data, but faces significant challenges in navigating regulatory hurdles and converting laboratory success into marketable products.

Cidara Therapeutics has announced promising results from its Phase 1 and 2b trials for its influenza preventative candidate, CD388, which demonstrated a high efficacy signal and statistically significant improvement in time-to-resolution of influenz…

Cidara Therapeutics Inc faces significant challenges in translating its scientific endeavors into profitable outcomes, with a negative price-to-earnings ratio and declining stock value raising concerns about its future prospects.

Cidara Therapeutics, a biotech company, has announced leadership changes to navigate market fluctuations and strengthen its strategic direction amidst financial challenges.